INCI name: Myristoyl Tetrapeptide-6, Glycerin, Butylene Glycol
Transforming growth factor (TGF-β), a member of a large family of secreted peptide growth factors, is known to play a prominent role in the accumulation of ECM (extracellular matrix) components by increasing the expression of ECM genes, such as collagen, elastin, fibronectin and proteoglycan. DermaPep™ A420, a mimic peptide of TGF-β, acts via TGF-β signaling pathway and thereby up-regulates ECM proteins such as collagen and fibronectin.
and in vivo
results show that DermaPep™ A420 significantly increases the expression of type I procollagen and fibronectin, efficiently reduces fine lines and wrinkles and helps to maintain dermal thickness.
Mechanism of Collagen Production
-Affinity for TGF-β receptor
-Induction of procollagen I gene expression
-Increase of procollagen I and fibronectin protein production
In vitro Efficacy
The efficacy of DermaPep™ A420 has been demonstrated in vitro
by measuring procollagen I protein and RNA expression on Hs68 fibroblast cell line.
Anti-wrinkle effect of DermaPep™ A420
DermaPep™ A420 was found to significantly increase the expression of type procollagen I mRNA and protein in human fibroblast Hs68 cells in vitro
In vivo Efficacy
The clinical test was performed on 32 Asian female volunteers (Bangkok), aged 35 to 60. 2% formula containing DermaPep™ A420 has been applied twice daily during 12 weeks on the crow’s feet area. Evaluation was performed by replica analysis (evaluation of the anti-wrinkle effect).
Wrinkle reduction effect
DermaPep™ A420 showed significant wrinkle reducing effect on healthy volunteers compared to the untreated area.
▶ Click here for MSDS, Technical Information